In this study, estimating the average treatment effect among the treated, first‐line GLP‐1 RA initiation was associated with a lower 1‐year risk of requiring additional glucose‐lowering treatment in both patients with prediabetes and diabetes, compared with starting with metformin. Here, GLP1R is linked to prediabetes syndrome.